Drug Profile
Research programme: cancer therapeutics - Pascal Biosciences
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator BioMmune Technologies; University of British Columbia
- Developer Pascal Biosciences; University of British Columbia
- Class Small molecules
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Canada
- 30 Mar 2017 BioMmune Technologies is now called Pascal Biosciences
- 03 Mar 2014 Early research in Cancer in Canada (unspecified route)